RxDoctor Payments Data

Cora Ridenour

Physician Assistant · Los Angeles, CANPI 1750168076

Payments from drug & device makers

$9,775in general payments, 2019–2025

Across 497 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Ardelyx, Inc.$618
  • QOL Medical, LLC$608
  • Takeda Pharmaceuticals U.S.A., Inc.$550
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$9,60898%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,775 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$101,070
Medicare patients
566
Services billed
1,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin46$102,660
LinzessLinaclotide92$69,788
CreonLipase/Protease/Amylase21$35,549
IbsrelaTenapanor Hcl11$18,945
TrulancePlecanatide11$10,509
MotegrityPrucalopride Succinate11$7,817
Mesalamine23$5,434
Omeprazole282$2,638
Famotidine175$1,982
Pantoprazole Sodium50$729
Dicyclomine Hcl32$517
Sucralfate39$448
Clarithromycin21$365
Neomycin Sulfate21$345
Amoxicillin23$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,232$113,16957 claims
AbbVieLinzess, Creon$2,067$105,337113 claims
Ardelyx, Inc.Ibsrela$618$18,94511 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$550$7,81711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →